Timber Pharmaceuticals, Inc. TMBR
Nov 28, 2023, 3:59 PM EST
52-week range unavailable
- Market cap
- 1.18M
- Shares out
- 3.43M
- Forward P/E
- -0.06
- Volume
- 130.46K
- Open
- 0.3411
- Previous close
- 0.3426
- Day's range
- 0.3202 – 0.35
- Beta
- -0.65
- Analysts
- Hold
- Earnings date
- Dec 4, 2023
2Y -1.7699 (-99.43%)
Key statistics
- Enterprise value
- -916.94K
- PEG ratio
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -6.18M
- Total cash
- 2.52M
- Total debt
- 545.13K
- Return on equity
- 0.00%
- Short % of float
- 0.23%
- 50-day average
- 1.88
- 200-day average
- 2.00
Analyst view
Consensus: hold
- Strong buy0
- Buy0
- Hold1
- Sell0
- Strong sell0
Next earnings
Dec 4, 2023
Expected Dec 4, 2023. Consensus EPS estimate -1.26.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Dec 4, 2023 | Sep 1, 2023 | 0.00 | — | — | — |
| Aug 21, 2023 | Jun 1, 2023 | -0.79 | — | — | — |
| May 15, 2023 | Mar 1, 2023 | -1.17 | — | — | — |
| Mar 30, 2023 | Dec 1, 2022 | -1.50 | — | — | — |
| Nov 14, 2022 | Sep 1, 2022 | -2.00 | — | — | — |
| Aug 11, 2022 | Jun 1, 2022 | -2.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 27, 2023 | HC Wainwright & Co. | down | Buy | Neutral |
| Apr 9, 2023 | HC Wainwright & Co. | reit | — | Buy |
About Timber Pharmaceuticals, Inc.
Timber Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-003, a proprietary formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist that is in preclinical development for the treatment of sclerotic skin diseases. It is also involved in the development of BPX-01, which is in Phase 3 topical minocycline for the treatment of inflammatory lesions of acne vulgaris; and BPX-04 that is a Phase 3 ready topical minocycline for the treatment of papulopustular rosacea. The company was founded in 2019 and is headquartered in Warren, New Jersey. On November 17, 2023, Timber Pharmaceuticals, Inc. along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- timberpharma.com
News
MSG Networks in talks to avoid bankruptcy — possibly with help of Amazon: sources 
Timber Pharmaceuticals, Inc., a LEO Pharma Company, Presents Late-Breaking Preliminary Results of TMB-001 in Moderate-to-Severe Congenital Ichthyosis (CI) at the 2024 AAD Annual Meeting 
LEO Pharma Finalizes Acquisition of Key Assets From Timber Pharmaceuticals 
Timber Pharmaceuticals Announces Commencement of NYSE American Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC Market 
Timber Pharmaceuticals Announces Commencement of NYSE American Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC Market 
Timber Pharmaceuticals Receives Court Approval of All “First Day” Motions to Support Business Operations & Discloses Communication From NYSE American 
NYSE American to Commence Delisting Proceedings Against Timber Pharmaceuticals, Inc. (TMBR) 
Timber Pharmaceuticals Announces NYSE Acceptance of Plan to Regain Listing Compliance 
TIMBER PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Timber Pharmaceuticals, Inc. - TMBR 
Timber (TMBR) to Get Acquired by LEO Pharma for $36M, Stock Up
Your note
Sign in to keep a note on TMBR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| COHEN DAVID E | Director | Stock Award(Grant) | Apr 13, 2023 | 6,100 |
| GAAL LUBOR | Director | Stock Award(Grant) | Apr 13, 2023 | 6,100 |
| KOCONIS JOHN | Chief Executive Officer | Stock Award(Grant) | Aug 17, 2023 | 70,785 |
| LUCCHESE JOSEPH | Chief Financial Officer | Stock Award(Grant) | Aug 17, 2023 | 35,193 |
| MENDELSOHN ALAN | Officer | Stock Award(Grant) | Aug 17, 2023 | 35,432 |
| PIROZZI GIANLUCA | Director | Stock Award(Grant) | Apr 13, 2023 | 6,100 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 1.13% | 38,687 | 94.01K | Jun 29, 2023 |
| Citadel Advisors Llc | 0.97% | 33,185 | 80.64K | Jun 29, 2023 |
| Geode Capital Management, LLC | 0.58% | 19,799 | 48.11K | Jun 29, 2023 |
| State Street Corporation | 0.42% | 14,442 | 35.09K | Jun 29, 2023 |
| Tower Research Capital LLC (TRC) | 0.09% | 2,924 | 7.11K | Jun 29, 2023 |
| UBS Group AG | 0.02% | 800 | 1.94K | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 1.13% | 38,687 | 94.01K | Jun 29, 2023 |
| Fidelity Extended Market Index Fund | 0.41% | 13,966 | 20.25K | May 30, 2023 |
| Fidelity Series Total Market Index Fund | 0.15% | 5,291 | 7.67K | May 30, 2023 |